$27.38
Value $3.4B
ARQT and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$27.38
Value $3.4B
$1,405.09
Value $1.33T
Arcutis Biotherapeutics (ARQT) has a market value of $3.4B and Eli Lilly and Company (LLY) $1.33T. Over the last year, with dividends, ARQT moved +9.5% and LLY +38.0%. The P/E is 113.5 for ARQT and 48.1 for LLY. Dividend yield: ARQT none, LLY 0.45%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ARQT$3.4B
LLY$1.33T
LLY is 390 times ARQT
Revenue, 12 months
ARQT$509M
LLY$86.5B
LLY is 170 times ARQT
Net income, 12 months
ARQT$30M
LLY$27.6B
LLY is 922 times ARQT
Operating margin
ARQT6.9%
LLY–
ROIC
ARQT9.0%
LLY35.5%
26.5 points apart
P/E
ARQT113.5
LLY48.1
ARQT is 2.4 times LLY
Dividend yield
ARQT0.0%
LLY0.4%
0.5 points apart
5-year return
ARQT+36.9%
LLY+469.6%
432.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ARQT+36.9%
LLY+469.6%
| Period | ARQTWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +9.5%Price +9.5% | +38.0%Price +37.1% |
| 3 years since November 17, 2023 | +1,242.2%+137.6% a yearPrice +1,242.2% | +142.4%+34.3% a yearPrice +137.6% |
| 5 years since November 16, 2021 | +36.9%+6.5% a yearPrice +36.9% | +469.6%+41.6% a yearPrice +445.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ARQTArcutis BiotherapeuticsLLYEli Lilly and Company
| Price | $27.38 | $1,405.09 |
|---|---|---|
| Market value | $3.4B | $1.33T |
| Enterprise value (EV) | – | $1.37T |
| P/E | 113.5 | 48.1 |
| P/E, 5-year median | – | 49.9 |
| P/B | 13.9 | 32.9 |
| EV/EBIT | – | 39.4 |
| Free cash flow yield | 1.8% | 1.5% |
| Revenue, 12 months | $509M | $86.5B |
|---|---|---|
| Net income, 12 months | $30M | $27.6B |
| Free cash flow, 12 months | $60M | $19.7B |
| Earnings per share, 12 months | $0.24 | $30.81 |
| Revenue growth, year on year | 91.3% | 44.7% |
| Revenue growth a year, past | – | +21.6%over 5 years |
| EPS growth a year, past | – | +27.6%over 5 years |
| Gross margin | 91.2% | 83.6% |
|---|---|---|
| Operating margin | 6.9% | – |
| Net margin | 5.9% | 31.9% |
| ROIC | 9.0% | 35.5% |
| ROE | 14.9% | 88.6% |
| Cash | $259M | $4.9B |
|---|---|---|
| Total debt | – | $49.5B |
| Net debt / EBITDA | – | 1.2 |
| Interest cover | 2.6× | 38.9× |
| Dividend yield | – | 0.4% |
|---|---|---|
| Dividend per share, 12 months | – | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | – | 0.3% |
| Shareholder yield | – | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.33T) is about 390.3 times Arcutis Biotherapeutics ($3.4B), at today's prices.
Since November 16, 2021, ARQT's price moved +36.9% and LLY's +445.6%. With dividends: ARQT +36.9% (+6.5% a year), LLY +469.6% (+41.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Arcutis Biotherapeutics and 0.45% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.
At today's price, the P/E is 113.5 for ARQT and 48.1 for LLY. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 5.9% for Arcutis Biotherapeutics and 31.9% for Eli Lilly and Company, and the operating margin 6.9% and –. Revenue was $509M and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.